For the Inventor, By the Inventor

Enter assignee name

Boulder, CO, United States of America

Bolder Biotechnology, Inc.

USPTO Granted Patents = 45

% Expired Patents = 62.2

CIPO Patents = 1

EPO Patents = 4

Forward Citations = 753

Loading Chart...

Loading Chart...

7 inventors (with patents filed for the assignee):

George N Cox (45 out of 58 patents)

Mary S Rosendahl (9 out of 18 patents)

Daniel H Doherty (9 out of 27 patents)

4. Christie M Orschell (5 out of 5 patents)

5. Meetha Manek Medhora (2 out of 2 patents)

6. Brian Fish (2 out of 2 patents)

7. Daniel J Doherty (1 out of 1 patent)

8. George N Iii Cox (0 patent)

Core Competencies:

Cysteine Variants

Growth Factors

Radiation Exposure

Granulocyte Colony-Stimulating Factor

Interleukin-11

Beta Interferon

Erythropoietin

Protein Derivatives

PEGylated Variants

Immunoglobulin Fusion Proteins

Growth Hormone Proteins

Treatment Methods

45 patents: Sort by Forward Citations

1. 12274736 - Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure (2025-04-14),

2. 11229683 - Hematopoietic growth factor proteins and analogs thereof and angiotensin converting enzyme inhibitors for treatment of radiation exposure (2022-01-25),

3. 10653752 - Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure (2020-05-19),

4. 10508131 - Cysteine analogs of exendin-4 (2019-12-17),

5. 10329337 - Method to increase the number of circulating platelets by administering PEGylated cysteine variants of IL-11 (2019-06-25),

6. 10016485 - Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure (2018-07-10),

7. 9637530 - Methods of preparing cysteine variants of human recombinant IL-11 (2017-05-02),

8. 9320777 - Methods and use of growth hormone supergene family protein analogs for treatment of radiation exposure (2016-04-26),

9. 9296804 - NH2-terminal glutamine modified cysteine variants of interferon gamma (2016-03-29),

10. 8957023 - Methods for making proteins containing free cysteine residues (2015-02-17),

11. 8932828 - Method for preparing recombinant granulocyte colony stimulating factor cysteine muteins (2015-01-13),

12. 8859497 - Method of treatment using cysteine mutants of beta interferon (2014-10-14),

13. 8748392 - Methods of treatment using cysteine variants of interleukin-11 (2014-06-10),

14. 8618256 - Cysteine variants of interferon gamma (2013-12-31),

15. 8617531 - Methods of making proteins and peptides containing a single free cysteine (2013-12-31),

Bolder Biotechnology, Inc. is a biotechnology company based in Boulder, Colorado, specializing in the development of innovative therapeutic solutions. The company focuses on hematopoietic growth factors and their applications in treating various medical conditions. Its research encompasses advanced topics such as interleukin-11, granulocyte colony-stimulating factor, and PEGylated proteins, among others. Bolder Biotechnology aims to enhance patient outcomes through its cutting-edge research in biologics and protein engineering.

Profile summary based on public USPTO records.

Company Badge

USPTO Data Jan 1 1976 - Sep 29 2026

45 Patents

#34 in Boulder, CO

#151 in Colorado

#7,766 in US

#15,408 in the World

Boulder, CO, United States of America

Bolder Biotechnology, Inc.

Forward Citations = 753

7 inventors:

George N Cox (45 out of 58 patents)

Mary S Rosendahl (9 out of 18 patents)

Daniel H Doherty (9 out of 27 patents)

4. Christie M Orschell (5 out of 5 patents)

5. Meetha Manek Medhora (2 out of 2 patents)

Please report any incorrect information to [email protected]

Loading…